耀速科技获晶泰科技数千万元战略投资，共同打造“AI+器官芯片”新范式

Core Viewpoint - The article discusses the strategic investment by XtalPi in Xellar Biosystems, focusing on the integration of AI and organ-on-a-chip technology to enhance drug development and safety evaluation processes, aiming to replace traditional animal testing methods with more efficient and reliable alternatives [1][2][5]. Group 1: Investment and Collaboration - Xellar Biosystems has completed a multi-million yuan strategic financing round led by XtalPi, with continued support from existing investors TianTu Investment and Yayi Capital [1]. - The investment will accelerate the development of Xellar's "3D-Wet-AI" closed-loop system, which integrates organ-on-a-chip technology, wet lab capabilities, and AI algorithms [1][2]. - XtalPi, a leader in AI drug and new materials research, will collaborate with Xellar to address industry challenges such as high-quality biological data generation and AI-assisted toxicology predictions [2][6]. Group 2: Technological Advancements - Xellar's EPIC™ platform combines microfluidic chip technology, disease modeling, and generative AI algorithms, enabling rapid construction of complex microenvironments and high-throughput experiments [4]. - The integration of AI with organ-on-a-chip technology is seen as a transformative approach in life sciences, potentially revolutionizing drug development processes [5][9]. - The collaboration aims to create a seamless connection between in vitro complex models and AI molecular generation and screening algorithms, enhancing drug development efficiency and success rates [2][6]. Group 3: Regulatory Environment - Global regulatory bodies are accelerating the adoption of alternatives to animal testing, with the FDA modernizing its standards to include non-animal methods for new drug IND submissions [3][4]. - Xellar is actively participating in standard validation alongside regulatory agencies, providing predictive analysis services for drug safety and efficacy [4][5]. Group 4: Market Position and Future Outlook - Xellar is positioned as a key player in the AI and organ-on-a-chip space, with a strong foundation in cell biology and disease modeling, which enhances its competitive edge [6][8]. - The partnership with XtalPi is expected to strengthen Xellar's capabilities in automation and intelligent modeling, paving the way for innovative solutions in non-animal testing and precision efficacy prediction [9].